MTLS News & Events

Materialise announced its plans to pursue an additional listing of its ordinary shares on Euronext Brussels, to complement the existing Nasdaq listing of its American depositary shares representing ordinary shares, and to launch an ADS buyback program.

Maintains FY25 adjusted EBIT view EUR6M-EUR10M.

Reports Q3 revenue EUR66.26M vs. EUR68.65M last year. CEO Brigitte de Vet-Veithen commented, "I am proud to report that we once more delivered a positive net result and strong cash flow in Q3 of this year. Our Materialise Medical segment posted a quarterly revenue record, growing by more than 10% compared to the same period in 2024, while macro-economic headwinds continued to impact our consolidated revenue, and, in particular, our Materialise Manufacturing segment. We further implemented targeted cost control measures designed to protect our operational profitability without compromising on our continued R&D investments to drive future growth."

Reports Q2 revenue EUR64.83M vs. EUR68.8M last year. CEO Brigitte de Vet-Veithen commented, "Our Materialise Medical segment once again demonstrated its resilience, growing by almost 17% compared to the same period of 2024. At the same time increasing geo-political uncertainty and sustained macro-economic headwinds negatively impacted revenues in our Materialise Manufacturing and Materialise Software segments, and therefore also our consolidated revenue in Q2 2025. Despite revenue pressure we were able to materially improve our operational profitability in Q2 2025 compared to prior periods through structural and targeted cost control. Unfavorable effects from exchange rate fluctuations significantly impacted our quarterly financials, but we nevertheless again reported a positive net result."